Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT05753280

Effect of Serum Vitamin D Level on the Efficacy of Peg-interferon Treatment in CHB

Conditions: Chronic Hepatitis b

Sex: All
Ages: 18 Years – 60 Years
Phase: PHASE4
Enrollment: 90
Sponsor: Third Affiliated Hospital, Sun Yat-Sen University

Location: China

Summary

In recent years, vitamin D (VD) has received much attention in the fields of host immune regulation, inflammation, fibrosis, cell proliferation and differentiation and tumor. VD works by binding to the vitamin D receptor (VDR). VDR is mainly distributed in giant cells, dendritic cells, T cells and lymphocytes. Four SNPs of VDRS have been most studied: TaqI (rs731236), FokI (rs10735810), ApaI (rs7975232), and BsmI (rs1544410). At present, more and more patients have been treated with oral nucleotide/nucleoside analogues (NAs) with direct antiviral drugs in China, and a large part of them show low expression of HBsAg. Clinical cure can be pursued for these patients, that is, HBsAg turns negative. A number of studies have been carried out at home and abroad.In this study, We will recruit CHB patients with low HBsAg levels. They all will receive pegylated interferon treatment and were randomly assigned to a vitamin D treatment or a control group. A final assessment will be made to determine whether vitamin D levels would affect the clearance rate of HBsAg.

Eligibility Criteria

Inclusion Criteria:1.According with the diagnosis of chronic hepatitis B in the guideline of China in 2015 2.18-60 years old 3.More than 1 year history of nucleot(s)ide analogues therapy with HBsAg ≤1500 IU/ml, negative HBeAg and HBV DNA<100 IU/ml 4.No contraindications of interferonExclusion Criteria:Allergy to interferonAlanine transaminase >10 times of upper limit of normal(ULN) or total bilirubin >2 times of ULNexisting or previous decompensated liver cirrhosisWhite blood cells or Platelet below the lower limit of normalexisting severe organ injurycombined with autoimmune diseases, psychiatric diseases, diabetes or thyroidismconfirmed or suspected malignant tumorsbefore or after transplantationusing immunosuppressorpregnant or having a planned parenthood in 2 yearsalcohol or drug addictedinfected by HIVany conditions that is unsuitable to interferon therapy according to the doctors' judgement

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05753280). StuddyBuddy aggregates publicly available trial information.